Mendel Goldfinger

Mendel Goldfinger

Auto-generated profile, based on publicly available information

Mendel Goldfinger

Department of Oncology, Montefiore Einstein Comprehensive Cancer Center. Albert Einstein College of Medicine, Bronx, NY.

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
VMVikas Mehta
Vikas Mehta
SGSANJAY GOEL
SANJAY GOEL
RKRafi Kabarriti
Rafi Kabarriti
DCDaniel Cole
Daniel Cole
MGMendel Goldfinger
Mendel Goldfinger
Amit VermaAmit Verma
Amit Verma
Patients with cancer are presumed to be at increased risk from COVID-19 infection–related fatality due to underlying malignancy, treatment-related immunosuppression, or increased comorbidities. A total of 218 COVID-19–positive patients from March 18, 2020, to April 8, 2020, with a malignant diagnosis were identified. A total of 61 (28%) patients with cancer died from COVID-19 with a case fatality rate (CFR) of 37% (20/54) for hematologic malignancies and 25% (41/164) for solid malignancies. Six of 11 (55%) patients with lung cancer died from COVID-19 disease. Increased mortality was significantly associated with older age, multiple comorbidities, need for ICU support, and elevated levels of D-dimer, lactate dehydrogenase, and lactate in multivariate analysis. Age-adjusted CFRs in patients with cancer compared with noncancer patients at our institution and New York City reported a significant increase in case fatality for patients with cancer. These data suggest the need for proactive strategies to reduce likelihood of infection and improve early identification in this vulnerable patient population. Significance: COVID-19 in patients with cancer is associated with a significantly increased risk of case fatality, suggesting the need for proactive strategies to reduce likelihood of infection and improve early identification in this vulnerable patient population. This article is highlighted in the In This Issue feature, p. 890

17 April 2020 in medRxiv
Verified
Preprint
Open access
PDF file
ASAditi Shastri
Aditi Shastri
JWJustin Wheat
Justin Wheat
SASachee Agrawal
Sachee Agrawal
NCNirjhar Chaterjee
Nirjhar Chaterjee
KPKith Pradhan
Kith Pradhan
JSJayanthi Shastri
Jayanthi Shastri
The novel coronavirus SARS-CoV2 has been observed to cause a higher incidence and greater severity of disease in males, as seen in multiple cohorts across the globe. The reasons for gender disparity in disease severity is unclear and can be due to host factors. To determine whether males have delayed viral clearance after infection, we evaluated the time to clearance in symptomatic patients tested by serial oropharyngeal/nasopharyngeal swabs followed by RT-PCR at a reference lab in Mumbai, India. A total of 68 subjects with median age of 37 years (3-75 range) were examined and included 48 (71%) males and 20 (29%) females. We observed that females were able to achieve viral clearance significantly earlier than males, with a median difference of 2 days in achieving a negative PCR result (P value = 0.038). Furthermore, examination of 3 families with both male and female patients followed serially, demonstrated that female members of the same household cleared the SARS-CoV2 infection earlier in each family. To determine reasons for delayed clearance in males, we examined the expression patterns of the SARS-CoV2 receptor, Angiotensin-converting enzyme 2 (ACE2), in tissue specific repositories. We observed that the testes was one of the highest sites of ACE2 expression in 3 independent RNA expression databases (Human Protein Atlas, FAMTOM5 and GETx). ACE2 was also determined to be highly expressed in testicular cells at the protein levels. Interestingly, very little expression of ACE2 was seen in ovarian tissue. Taken together, these observations demonstrate for the first time that male subjects have delayed viral clearance of SARS-CoV2. High expression of ACE2 in testes raises the possibility that testicular viral reservoirs may play a role in viral persistence in males and should be further investigated.

15 December 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
PZPhaedon Dimitrios Zavras
Phaedon Dimitrios Zavras
ASAditi Shastri
Aditi Shastri
MGMendel Goldfinger
Mendel Goldfinger
Amit VermaAmit Verma
Amit Verma
YSYogen Saunthararajah
Yogen Saunthararajah
Purpose: Azacitidine and decitabine are hypomethylating agents (HMA), that is, both inhibit and deplete DNA methyltransferase 1 (DNMT1). HMAs are standard single-agent therapies for myelodysplastic syndromes and acute myelogenous leukemias. Several attempts to improve outcomes by combining HMAs with investigational agents, excepting with the BCL2-inhibitor venetoclax, have failed in randomized clinical trial (RCT) evaluations. We extract lessons from decades of clinical trials to thereby inform future work. Experimental Design: Serial single-agent clinical trials were analyzed for mechanism and pathway properties of HMAs underpinning their success, and for rules for dose and schedule selection. RCTs were studied for principles, dos and don'ts for productive combination therapy. Results: Single-agent HMA trial results encourage dose and schedule selection to increase S-phase–dependent DNMT1 targeting, and discourage doses that cause indiscriminate antimetabolite effects/cytotoxicity, because these attrit myelopoiesis reserves needed for clinical response. Treatment-related myelosuppression should prompt dose/frequency reductions of less active investigational agents rather than more active HMA. Administering cytostatic agents concurrently with HMA can antagonize S-phase–dependent DNMT1 targeting. Supportive care that enables on-time administration of S-phase (exposure-time)–dependent HMA could be useful. Agents that manipulate pyrimidine metabolism to increase HMA pro-drug processing into DNMT1-depleting nucleotide, and/or inhibit other epigenetic enzymes implicated in oncogenic silencing of lineage differentiation, could be productive, but doses and schedules should adhere to therapeutic index/molecular–targeted principles already learned. Conclusions: More than 40 years of clinical trial history indicates mechanism, pathway, and therapeutic index properties of HMAs that underpin their almost exclusive success and teaches lessons for selection and design of combinations aiming to build on this treatment foundation.

1 March 2022 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
MGMendel Goldfinger
Mendel Goldfinger
DCDennis L Cooper
Dennis L Cooper

20 February 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SASarah Aminov
Sarah Aminov
OGOrsi Giricz
Orsi Giricz
DMDavid T. Melnekoff
David T. Melnekoff
RSR. Alejandro Sica
R. Alejandro Sica
VPVeronika Polishchuk
Veronika Polishchuk
Amit VermaAmit Verma
Amit Verma
While therapies targeting CD19 by antibodies, chimeric antigen receptor T cells (CAR-T), and T cell engagers have improved the response rates in B cell malignancies, the emergence of resistant cell populations with low CD19 expression can lead to relapsed disease. We developed an in vitro model of adaptive resistance facilitated by chronic exposure of leukemia cells to a CD19 immunotoxin. Single-cell RNA-Seq (scRNA-Seq) showed an increase in transcriptionally distinct CD19 lo populations among resistant cells. Mass cytometry demonstrated that CD22 was also decreased in these CD19 lo -resistant cells. An assay for transposase-accessible chromatin with sequencing (ATAC-Seq) showed decreased chromatin accessibility at promoters of both CD19 and CD22 in the resistant cell populations. Combined loss of both CD19 and CD22 antigens was validated in samples from pediatric and young adult patients with B cell acute lymphoblastic leukemia (B-ALL) that relapsed after CD19 CAR-T–targeted therapy. Functionally, resistant cells were characterized by slower growth and lower basal levels of MEK activation. CD19 lo resistant cells exhibited preserved B cell receptor signaling and were more sensitive to both Bruton’s tyrosine kinase (BTK) and MEK inhibition. These data demonstrate that resistance to CD19 immunotherapies can result in decreased expression of both CD19 and CD22 and can result in dependency on BTK pathways.

28 November 2024 in Blood
Verified
Journal Article
Open access
MGMendel Goldfinger
Mendel Goldfinger
IMIoannis Mantzaris
Ioannis Mantzaris
ASAditi Shastri
Aditi Shastri
YSYogen Saunthararajah
Yogen Saunthararajah
KGKira Gritsman
Kira Gritsman
Amit VermaAmit Verma
Amit Verma
A metronomic, low-dose schedule of decitabine and venetoclax was safe and effective in myeloid malignancies with few dose reductions or interruptions in an older diverse population. Median overall survival for patients with acute myeloid leukemia and a TP53-mutation was 16.1 and 11.3 months, respectively. This trial was registered at www.clinicaltrials.gov as #NCT05184842.